title: Sulochrin inhibits eosinophil activation and chemotaxis.
abstract: OBJECTIVE
  Because eosinophils likely play important roles in the pathophysiology of allergic diseases, specific inhibitors of eosinophils may be desirable to treat such diseases. To evaluate the capacity of a novel compound, sulochrin, as an inhibitor of eosinophilic inflammation, we examined the effects of this compound on various effector functions of eosinophils.
  
  
  METHODS
  We examined the effects of sulochrin on degranulation of human eosinophils stimulated with platelet-activating factor (PAF) or Sepharose 4B beads coated with secretory IgA (sIgA) or IgG. The effects of sulochrin on other effector functions of human eosinophils, including superoxide anion (O2-) production, leukotriene (LT) C4 release, and interleukin (IL)-8 production induced by sIgA-beads were also studied. Finally, using PAF and LTB4 as chemoattractants, we evaluated the potency of sulochrin to inhibit eosinophil migration in vitro and in vivo.
  
  
  RESULTS
  Sulochrin inhibited EDN release by eosinophils stimulated with sIgA-beads. IgG-beads and PAF in a concentration-dependent manner; IC50 values were 0.75 microM, 0.30 microM and 0.03 microM. Eosinophil O2- production, LTC4 release, and IL-8 production were also inhibited by sulochrin. Furthermore, PAF-induced chemotaxis of human eosinophils and LTB4-induced chemotaxis of guinea pig eosinophils were abolished by 1 microM of sulochrin. Finally, sulochrin potently inhibited LTB4-induced infiltration of eosinophils into the skin of guinea-pig in vivo.
  
  
  CONCLUSIONS
  These results suggest that sulochrin is a potent inhibitor of various effector functions of eosinophils. Sulochrin and its derivatives may be useful in the development of therapeutic approaches for patients with allergic diseases.
authors.affiliation: Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, Gunma, Japan. hohashi@kirin.co.jp
authors.forename: H
authors.initials: H
authors.lastname: Ohashi
authors.forename: Y
authors.initials: Y
authors.lastname: Motegi
authors.forename: H
authors.initials: H
authors.lastname: Kita
authors.forename: G J
authors.initials: GJ
authors.lastname: Gleich
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: M
authors.initials: M
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: H
authors.initials: H
authors.lastname: Fukamachi
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D015550:Cell Degranulation / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000502:physiology*; D006168:Guinea Pigs; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D016209:Interleukin-8 / Q000096:biosynthesis; D007975:Leukotriene B4 / Q000494:pharmacology; D017997:Leukotriene C4 / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology; D012685:Sepharose; D013481:Superoxides / Q000378:metabolism
chemical_list: D018926:Anti-Allergic Agents; D001565:Benzoates; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D016209:Interleukin-8; D010972:Platelet Activating Factor; D013481:Superoxides; D007975:Leukotriene B4; D017997:Leukotriene C4; C111298:sulochrin; D012685:Sepharose